Treatment Registry
TR-0471 ActiveRecorded September 2026Last verified October 2026

Compounded semaglutide

Sold by Royal Medical Center · Injection, vial · every compounded semaglutide record

Price

TermPublished rateCharged today
Compounded GLP-1 program, starting price

Price conditions have not been established; the quoted figure is not a verified recurring rate.

“Compounded GLP-1 Tirzepatide & Semaglutide Starting at $67 per month Includes all medications Includes supplies and injections Includes physician consultations and follow-ups Includes lab monitoring and adjustments”

$67Published figureCharged todayNot verified
Price sources
Visit Royal Medical Center

We earn nothing from this link. It opens Royal Medical Center's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PharmacyBelmar Pharma Solutions
StatesNot disclosed
PrescriberNot disclosed
CancellationNot disclosed
MembershipNot disclosed
Consult fee$0, included in program price. Physician consultations and follow-ups are included in the advertised weight-loss program.

Recorded from royalmedicalcenters.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — A single 'starting at $67/month' price is published for a combined tirzepatide-and-semaglutide compounded program; the page does not break the price out per drug, so the same figure was recorded against both. No page found stating served states, prescriber synchronicity, cancellation terms, or a membership fee — checked the men's FAQ, women's FAQ, weight-loss page, and HIPAA policy without finding any of these.
  2. 2. October 2026 — Royal Medical Center includes physician follow-ups, medication, supplies and lab monitoring in its weight-loss program, and identifies Belmar Pharma Solutions as its dispensing pharmacy. Its current starting-price advertisement does not identify the medication or full payment schedule. Confirm a quote for this specific treatment before enrolling.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0471
Medication category
compounded semaglutide
Readings
2

Related records

Cite this entry

Treatment Registry. (2026). Royal Medical Center — compounded semaglutide (TR-0471). Last verified October 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0471

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.